| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0041-1345(98)01982-4 |
| P698 | PubMed publication ID | 10083557 |
| P2093 | author name string | F Stuart | |
| S Cho | |||
| R Johnson | |||
| B Nashan | |||
| H Ekberg | |||
| D Kuypers | |||
| E Ramos | |||
| F Vincenti | |||
| J Grinyo | |||
| C Brattstrom | |||
| P2860 | cites work | Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy | Q41184484 |
| Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group | Q47887130 | ||
| Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group | Q74038855 | ||
| P433 | issue | 1-2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1246-1248 | |
| P577 | publication date | 1999-02-01 | |
| P1433 | published in | Transplantation Proceedings | Q7834825 |
| P1476 | title | Can antibody prophylaxis allow sparing of other immunosuppressives? | |
| P478 | volume | 31 |
| Q43927823 | A calcineurin antagonist-free induction immunosuppression strategy for delayed graft function in renal transplantation |
| Q43640089 | An induction versus no-induction protocol in anticalcineurin-based immunosuppression using very low-dose steroids |
| Q73337735 | Anti-interleukin 2-receptor antibodies: a comparative study with polyclonal antibodies in kidney transplantation: preliminary results |
| Q44256933 | Basiliximab-sirolimus-prednisone induction regimen followed by delayed low-dose cyclosporine in renal transplant recipients of living donors |
| Q44216320 | Bolus anti-thymocyte globulin induction in renal transplant recipients: a comparison with conventional ATG or anti-interleukin-2 receptor antibody induction |
| Q44524563 | Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years |
| Q37900647 | Current landscape for T-cell targeting in autoimmunity and transplantation |
| Q57702959 | Cyclosporine prolongs delayed graft function in kidney transplantation: are rabbit anti-human thymocyte globulins the answer? |
| Q33826215 | Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients |
| Q40413089 | Delayed renal graft function: the influence of immunosuppression |
| Q43423598 | Immunosuppression for delayed or slow graft function in primary cadaveric renal transplantation: use of low dose tacrolimus therapy with post-operative administration of anti-CD25 monoclonal antibody |
| Q74348272 | Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients |
| Q33844441 | Nephrotoxicity of calcineurin inhibitors: new therapeutic approaches |
| Q34621443 | Options for induction immunosuppression in liver transplant recipients |
| Q73934839 | Overcoming toxicities: new regimens |
| Q34547749 | Reducing adverse effects of immunosuppressive agents in kidney transplant recipients |
| Q44402537 | Sirolimus Prolongs Recovery from Delayed Graft Function After Cadaveric Renal Transplantation |
| Q73314779 | The interleukin-2 inhibitors and their role in low-toxicity regimens |
| Q36675465 | The role of basiliximab induction therapy in organ transplantation |
| Q44608602 | The role of the protocol biopsies in renal allograft recipients |
| Q74264520 | [New induction immunosuppression treatments in kidney transplantation] |
Search more.